ICER's launch price and access report: 5 key takeaways and 5 questions we should all be asking. [PDF]
Agboola F, Emond SK.
europepmc +1 more source
Health and social policies to advance Brazil's End TB agenda during and after COVID-19: An analysis from tripartite governance and normative innovation perspectives. [PDF]
Ribeiro NM +15 more
europepmc +1 more source
Financial reimbursement incentives in the use of biosimilars for rheumatoid arthritis in Japan. [PDF]
Mamiya H, Fukasawa T, Kawakami K.
europepmc +1 more source
Establish a PrEP (Pre-Exposure Prophylaxis) Epidemiology, Modeling, and Surveillance (PREMISE) System to Analyze Trends in PrEP Uptake and the Impact of PrEP Programs and Policies: Protocol for a Natural Experiment and Modeling Study in the United States. [PDF]
Siegler AJ +9 more
europepmc +1 more source
Indonesian pharmaceutical dataset for self-medication. [PDF]
Wiputra R +5 more
europepmc +1 more source
Doxorubicin and Edelfosine Combo-Loaded Lipid-Polymer Hybrid Nanoparticles for Synergistic Anticancer Effect Against Drug-Resistant Osteosarcoma [Retraction]. [PDF]
europepmc +1 more source
Drugs legislation : European drug policies or drug policies in Europe?
openaire +1 more source
Related searches:
There are important gender differences in the use, experience, and consequences of substance use. Accordingly, drug policies formulated to address problems related to substance use often either implicitly or explicitly contain gendered assumptions about drugs and their effects and harms, and when implemented these policies have gendered impacts – that ...
Natalie Thomas, Jennifer Juckel
openaire +2 more sources

